RECENT COMMENTS

Constantinos Zambirinis (Thyroid cancer management): As you mentioned above, differentiated thyroid cancer is followed after treatment with the thyroglob [...]   »Read more

Dr Lobna Sedky (Serigne Magueye Gueye): Within Africa,the scope of cancer differs even between various geographic regions. Being an oncologi [...]   »Read more

DR PUSHKAL DWIVEDI (World Cancer Declaration): I FULLY AGREE!   »Read more

Dr Olayinka O Adegbehingbe (World Cancer Declaration): Dear Prof Franco Cavalli, The World Cancer Declaration is great and impacts in developing countries [...]   »Read more

Tung Dinh Nguyen (World Cancer Declaration): Dear Dr F Cavalli, I have had a lot of chance to see Dr F. Cacalli In Hue, Vietnam. The World Ca [...]   »Read more

Editorial Advisors

 

  • Fatima Cardoso
  • Franco Cavalli
  • Alberto Costa
  • Jacques Bernier
  • Vincent T. DeVita

 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

GR109 - The challenge of ovarian cancer in relapse

GR110 - Permanent implant prostate brachytherapy: The state-of-the-art

GR111 - Breast cancer chemoprevention: What is new?

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, GlaxoSmithKline, Merck and Novartis.